Cargando…

Current Biomarker Strategies in Autoimmune Neuromuscular Diseases

Inflammatory neuromuscular disorders encompass a diverse group of immune-mediated diseases with varying clinical manifestations and treatment responses. The identification of specific biomarkers has the potential to provide valuable insights into disease pathogenesis, aid in accurate diagnosis, pred...

Descripción completa

Detalles Bibliográficos
Autores principales:	Oeztuerk, Menekse, Henes, Antonia, Schroeter, Christina B., Nelke, Christopher, Quint, Paula, Theissen, Lukas, Meuth, Sven G., Ruck, Tobias
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10605022/ https://www.ncbi.nlm.nih.gov/pubmed/37887300 http://dx.doi.org/10.3390/cells12202456

Ejemplares similares

Crosstalk of Microorganisms and Immune Responses in Autoimmune Neuroinflammation: A Focus on Regulatory T Cells
por: Schroeter, Christina B., et al.
Publicado: (2021)

Enjoy Carefully: The Multifaceted Role of Vitamin E in Neuro-Nutrition
por: Regner-Nelke, Liesa, et al.
Publicado: (2021)

Introducing electronic monitoring of disease activity in patients with chronic inflammatory demyelinating polyneuropathy (EMDA CIDP): trial protocol of a proof of concept study
por: Masanneck, Lars, et al.
Publicado: (2023)

Immune Checkpoint Inhibition–Related Myasthenia-Myositis-Myocarditis Responsive to Complement Blockade
por: Nelke, Christopher, et al.
Publicado: (2023)

Senescent fibro-adipogenic progenitors are potential drivers of pathology in inclusion body myositis
por: Nelke, Christopher, et al.
Publicado: (2023)

Cladribine treatment improves cortical network functionality in a mouse model of autoimmune encephalomyelitis
por: Schroeter, Christina B., et al.
Publicado: (2022)

Skeletal muscle as potential central link between sarcopenia and immune senescence
por: Nelke, Christopher, et al.
Publicado: (2019)

Bilateral Vocal Fold Paralysis in Myasthenia Gravis: A Case Report and Literature Review
por: Nelke, Christopher, et al.
Publicado: (2020)

Activation of non-classical NMDA receptors by glycine impairs barrier function of brain endothelial cells
por: Epping, Lisa, et al.
Publicado: (2022)

Eculizumab versus rituximab in generalised myasthenia gravis
por: Nelke, Christopher, et al.
Publicado: (2022)

Treatment approaches to patients with multiple sclerosis and coexisting autoimmune disorders
por: Brummer, Tobias, et al.
Publicado: (2021)

Independent risk factors for myasthenic crisis and disease exacerbation in a retrospective cohort of myasthenia gravis patients
por: Nelke, Christopher, et al.
Publicado: (2022)

Eculizumab treatment alters the proteometabolome beyond the inhibition of complement
por: Nelke, Christopher, et al.
Publicado: (2023)

Myositis in Germany: epidemiological insights over 15 years from 2005 to 2019
por: Pawlitzki, Marc, et al.
Publicado: (2022)

Driving time-based identification of gaps in specialised care coverage: An example of neuroinflammatory diseases in Germany
por: Masanneck, Lars, et al.
Publicado: (2023)

High-Dimensional Cytometry Dissects Immunological Fingerprints of Idiopathic Inflammatory Myopathies
por: Nelke, Christopher, et al.
Publicado: (2022)

Alemtuzumab-induced immune phenotype and repertoire changes: implications for secondary autoimmunity
por: Ruck, Tobias, et al.
Publicado: (2022)

One Brain—All Cells: A Comprehensive Protocol to Isolate All Principal CNS-Resident Cell Types from Brain and Spinal Cord of Adult Healthy and EAE Mice
por: Schroeter, Christina B., et al.
Publicado: (2021)

The Innate Immune Response Characterizes Posterior Reversible Encephalopathy Syndrome
por: Nelke, Christopher, et al.
Publicado: (2021)

Vaccine-based clinical protection against SARS-CoV-2 infection and the humoral immune response: A 1-year follow-up study of patients with multiple sclerosis receiving ocrelizumab
por: Räuber, Saskia, et al.
Publicado: (2022)

Blood-brain barrier modeling: challenges and perspectives
por: Ruck, Tobias, et al.
Publicado: (2015)

Classifying flow cytometry data using Bayesian analysis helps to distinguish ALS patients from healthy controls
por: Räuber, Saskia, et al.
Publicado: (2023)

Failed, Interrupted, or Inconclusive Trials on Immunomodulatory Treatment Strategies in Multiple Sclerosis: Update 2015–2020
por: Rolfes, Leoni, et al.
Publicado: (2020)

Nitrosative Stress Molecules in Multiple Sclerosis: A Meta-Analysis
por: Förster, Moritz, et al.
Publicado: (2021)

Failed, Interrupted, or Inconclusive Trials on Neuroprotective and Neuroregenerative Treatment Strategies in Multiple Sclerosis: Update 2015–2020
por: Huntemann, Niklas, et al.
Publicado: (2021)

Autoimmune Neuromuscular Disorders
por: Kraker, Jessica, et al.
Publicado: (2011)

Alemtuzumab in Multiple Sclerosis: Mechanism of Action and Beyond
por: Ruck, Tobias, et al.
Publicado: (2015)

ALAIN01—Alemtuzumab in autoimmune inflammatory neurodegeneration: mechanisms of action and neuroprotective potential
por: Ruck, Tobias, et al.
Publicado: (2016)

Autoimmune Neuromuscular Disorders in Childhood
por: McMillan, Hugh J., et al.
Publicado: (2011)

Autoimmune Channelopathies at Neuromuscular Junction
por: Huang, Kun, et al.
Publicado: (2019)

Pretreatment anti-thyroid autoantibodies indicate increased risk for thyroid autoimmunity secondary to alemtuzumab: A prospective cohort study
por: Ruck, Tobias, et al.
Publicado: (2019)

Inclusion body myositis and associated diseases: an argument for shared immune pathologies
por: Nelke, Christopher, et al.
Publicado: (2022)

Immune response to SARS-CoV-2 vaccination in relation to peripheral immune cell profiles among patients with multiple sclerosis receiving ocrelizumab
por: Räuber, Saskia, et al.
Publicado: (2022)

Ocrelizumab initiation in patients with MS: A multicenter observational study
por: Ellwardt, Erik, et al.
Publicado: (2020)

Therapeutic Apheresis in Acute Relapsing Multiple Sclerosis: Current Evidence and Unmet Needs—A Systematic Review
por: Rolfes, Leoni, et al.
Publicado: (2019)

Ocrelizumab Extended Interval Dosing in Multiple Sclerosis in Times of COVID-19
por: Rolfes, Leoni, et al.
Publicado: (2021)

S1PR-1/5 modulator RP-101074 shows beneficial effects in a model of central nervous system degeneration
por: Sindi, Mustafa, et al.
Publicado: (2023)

Long-term efficacy of alemtuzumab in polymyositis
por: Ruck, Tobias, et al.
Publicado: (2015)

Murine K(2P)5.1 Deficiency Has No Impact on Autoimmune Neuroinflammation due to Compensatory K(2P)3.1- and K(V)1.3-Dependent Mechanisms
por: Bittner, Stefan, et al.
Publicado: (2015)

Vitiligo after alemtuzumab treatment: Secondary autoimmunity is not all about B cells
por: Ruck, Tobias, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_69p64fa77h9fo1e9m5un0ts6jk